Sera Prognostics Inc logo

Sera Prognostics Inc(SERA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.01
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SERA

11/13/2026: SERA (1-star) is currently NOT-A-BUY. Pass it for now.

Sera Prognostics is a precision medicine company specializing in proteomic biomarker diagnostics, primarily focused on identifying risks for preterm birth through its PreTRM test. The company’s primary strength lies in its robust clinical data and specialized technology platform within the prenatal healthcare space. Its key investment narrative centers on becoming a standard of care for pregnancy risk assessment, though success depends on scaling commercial adoption and securing broader insurance coverage. Key risks include intense competition from established laboratory giants, high operating expenses, and the inherent challenges of clinical commercialization. The stock is best suited for growth-oriented investors with a high risk tolerance.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers potential for high growth if it successfully scales its diagnostic testing business.
Momentum investorMixed fitMomentum is conditional on positive clinical or commercial milestones and sustained upward price signals.
Value investorWeak fitAs an early-stage biotech, the company lacks the consistent earnings or assets typical of value investing.
Dividend investorWeak fitThe company is in a growth-focused, cash-consuming phase and does not pay dividends.
Low-risk investorWeak fitHigh volatility and operational uncertainty make this stock unsuitable for conservative, risk-averse portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is susceptible to significant price swings due to clinical results and market sentiment.
Valuation riskHighValuation is often speculative, tied to potential future market adoption rather than current earnings.
Competition risk (Diagnostics/Laboratory Services)HighThe company competes against well-entrenched, large-scale laboratory service providers.
Business qualityMediumWhile the technology is innovative, the business model is still proving its path to profitability.
Dividend incomeLow / noneIncome investors should not look here, as all capital is directed toward growth and operations.
Execution riskHighSuccess depends heavily on commercializing PreTRM and gaining physician trust.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 79.94M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) 31.2K shares
Beta 1.15
52 Weeks Range 1.56 - 3.85
Updated Date 11/14/2026
52 Weeks Range 1.56 - 3.85
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.67

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -43.01%
Avg. Invested days 18
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SERA receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
SERA has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+2.9%) is partially offset by weak cash generation (FCF margin -32529.6%), moderate revenue growth (+5.2%), weak profitability (net margin -39417.3%).

Financial Health Rating

★★★★★
SERA's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 16.3%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is SERA's strongest growth driver at +5.2% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while free-cash-flow growth (-72.3%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 56.9% and approximately 72.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 12.01% supports management-shareholder alignment.

Top 5 Institutional Investors

Baker Bros Advisors LP 13.83%
Whetstone Capital Advisors, LLC 8.32%
Aberdeen Group PLC 6.92%
Vivo Capital, LLC 4.15%
Vanguard Capital Management, LLC 3.26%

Unit Economics (Per $1K Revenue)

★★★★★
SERA generates approximately $-1,025 of gross profit, $-450,667 of operating income, and $-325,296 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
SERA has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Small / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Diagnostic TestingRevenue generated from the sale and processing of the PreTRM test for patients and healthcare providers.The company makes money by selling a specialized pregnancy diagnostic test, aiming to become a standard tool for doctors.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 37.93M
Price to Sales(TTM) 832.68
Enterprise Value 37.93M
Price to Sales(TTM) 832.68
Enterprise Value to Revenue 395.09
Enterprise Value to EBITDA -0.61
Shares Outstanding 38.80M
Shares Floating 28.02M
Shares Outstanding 38.80M
Shares Floating 28.02M
Percent Insiders 12.01
Percent Institutions 56.87

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.